INVO Fertility Announces Third Quarter 2025 Financial Results
INVO Fertility (Nasdaq: IVF) reported Q3 2025 results on November 17, 2025, showing continued top-line growth but ongoing losses. Revenue was $1.757M, up 23% YoY; consolidated clinic revenue rose 21% YoY to $1.722M, and revenue from all clinics was $1.995M, up 18% YoY. The company reported a net loss of $2.6M versus a $1.6M loss a year earlier, and Adjusted EBITDA of $(947,568), roughly flat year-over-year.
Operational highlights include 23% organic clinic growth, 130% YoY INVOcell device revenue growth, expanded telehealth and marketing initiatives, an acquisition pipeline, and efforts to improve clinic efficiencies and integrate AI scribe technology.
INVO Fertility (Nasdaq: IVF) ha riportato i risultati del Q3 2025 il 17 novembre 2025, mostrando una crescita continua del fatturato ma perdite in corso. Entrate sono state $1.757M, in crescita 23% YoY; le entrate consolidate delle cliniche sono aumentate del 21% YoY a $1.722M, e le entrate di tutte le cliniche sono $1.995M, in crescita 18% YoY. L'azienda ha riportato una perdita netta di $2.6M rispetto a una perdita di $1.6M nello stesso periodo dell'anno precedente, e un Adjusted EBITDA di $(947,568), praticamente stabile rispetto all'anno precedente.
Gli highlight operativi includono una crescita organica delle cliniche del 23%, un aumento del 130% YoY delle entrate derivanti dai dispositivi INVOcell, l'espansione di telemedicina e iniziative di marketing, un pipeline di acquisizioni e sforzi per migliorare l'efficienza delle cliniche e integrare la tecnologia di scriba AI.
INVO Fertility (Nasdaq: IVF) informó los resultados del tercer trimestre de 2025 el 17 de noviembre de 2025, mostrando un crecimiento continuo de los ingresos pero pérdidas en curso. Los ingresos fueron $1.757M, con un crecimiento del 23% interanual; los ingresos consolidados de las clínicas aumentaron un 21% interanual hasta $1.722M, y los ingresos de todas las clínicas fueron $1.995M, con un crecimiento del 18% interanual. La compañía informó una pérdida neta de $2.6M frente a una pérdida de $1.6M hace un año, y un EBITDA ajustado de $(947,568), prácticamente estable año tras año.
Entre los aspectos operativos se destacan un crecimiento orgánico de clínicas del 23%, un crecimiento del 130% interanual de los ingresos por dispositivos INVOcell, expansión de telemedicina e iniciativas de marketing, un pipeline de adquisiciones y esfuerzos para mejorar la eficiencia de las clínicas e incorporar tecnología de escriba AI.
INVO Fertility (나스닥: IVF)는 2025년 11월 17일 2025년 3분기 실적을 발표했고, 매출은 지속적으로 성장했으나 손실은 계속되었습니다. 매출은 $1.757M로 전년 대비 23% 증가했으며; 클리닉의 연결 매출은 전년 대비 21% 증가하여 $1.722M, 모든 클리닉의 매출은 $1.995M로 전년 대비 18% 증가했습니다. 회사는 전년 동기 대비 $2.6M의 순손실을 보고했고, 조정 EBITDA는 $(947,568)로 거의 동일했습니다.
운영 하이라이트로는 23%의 유기적 클리닉 성장, INVOcell 기기 매출이 전년 대비 130% 증가, 텔레헬스 및 마케팅 이니셔티브 확대, 인수 파이프라인 및 클리닉 효율성 향상과 AI 기록 보조 기술의 통합 노력이 포함됩니다.
INVO Fertility (Nasdaq : IVF) a publié les résultats du troisième trimestre 2025 le 17 novembre 2025, montrant une croissance continue du chiffre d’affaires mais des pertes en cours. Le chiffre d’affaires s’est élevé à $1.757M, en hausse de 23% sur un an; le chiffre d’affaires consolidé des cliniques a augmenté de 21% sur un an pour atteindre $1.722M, et le chiffre d’affaires de toutes les cliniques était de $1.995M, en hausse de 18% sur un an. La société a enregistré une perte nette de $2.6M contre une perte de $1.6M il y a un an, et un EBITDA ajusté de $(947,568), pratiquement stable d’année en année.
Parmi les points opérationnels figurent une croissance organique des cliniques de 23%, une croissance de 130% sur 1 an des revenus des dispositifs INVOcell, le développement de la télémédecine et des initiatives marketing, un pipeline d’acquisitions et des efforts pour améliorer l’efficacité des cliniques et intégrer la technologie de rédacteur IA.
INVO Fertility (Nasdaq: IVF) berichtete über die Ergebnisse des dritten Quartals 2025 am 17. November 2025, wobei ein fortgesetztes Top-Line-Wachstum, aber anhaltende Verluste festgestellt wurden. Umsatz betrug $1.757M, ein Anstieg von 23% YoY; der konsolidierte Klinikumsatz stieg um 21% YoY auf $1.722M, und der Umsatz aller Kliniken betrug $1.995M, ein Anstieg von 18% YoY. Das Unternehmen meldete einen Nettoverlust von $2.6M gegenüber einem Verlust von $1.6M im Vorjahr, und ein Adjusted EBITDA von $(947,568), nahezu unverändert im Jahresvergleich.
Zu den operativen Highlights gehören 23% organische Klinikwachstums, 130% YoY INVOcell-Geräteumsatzwachstum, erweiterte Telemedizin- und Marketinginitiativen, eine Akquisitionspipeline und Bemühungen, Klinik-Effizienz zu verbessern und AI-Scribe-Technologie zu integrieren.
INVO Fertility (ناسداك: IVF) أبلغت عن نتائج الربع الثالث 2025 في 17 نوفمبر 2025، مع استمرار النمو في الإيرادات لكن خسائر جارية. الإيرادات كانت $1.757M، بزيادة 23% على أساس سنوي; ارتفع إجمالي إيرادات العيادات المجمعة بنسبة 21% على أساس سنوي ليصل إلى $1.722M, وكانت إيرادات جميع العيادات $1.995M، بارتفاع 18% على أساس سنوي. أعلنت الشركة عن خسارة صافية قدرها $2.6M مقابل خسارة قدرها $1.6M قبل عام، و EBITDA المعدل بقيمة $(947,568)، شبه ثابت على مدار السنة.
ومن أبرز الإنجازات التشغيلية نمو العيادات بنسبة 23% عضويًا، نمو الإيرادات من أجهزة INVOcell بنسبة 130% على أساس سنوي, توسيع خدماتها في التطبيب عن بُعد ومبادرات التسويق، خط أنابيب الاستحواذات وجهود لتحسين كفاءة العيادات ودمج تكنولوجيا كاتب الذكاء الاصطناعي.
- Total revenue +23% YoY to $1.757M
- Consolidated clinic revenue +21% YoY to $1.722M
- All-clinic revenue +18% YoY to $1.995M
- INVOcell device revenue +130% YoY
- Net loss widened to $2.6M from $1.6M
- Adjusted EBITDA negative $(947,568), essentially unchanged YoY
Insights
Mixed quarter: clear top-line growth but persistent losses and flat adjusted EBITDA keep near-term impact neutral.
Revenue rose to
Despite revenue gains, the company reported a larger net loss of
Operational drivers include organic clinic growth, telehealth expansion, and a notable
SARASOTA, Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced third quarter 2025 financial results.
Q3 2025 Financial Highlights (all metrics compared to Q3 2024 unless otherwise noted)
- Revenue was
$1,757,094 , an increase of23% compared to$1,433,151. - Consolidated clinic revenue from the Company's INVO Center in Atlanta, Georgia, and fertility clinic in Madison, Wisconsin, increased
21% to$1,722,223 , compared to$1,418,011. - Revenue from all clinics, including both consolidated and equity method clinics, was
$1,995,007 , an increase of18% compared to$1,686,093. - Net loss was
$(2.6) million compared to$(1.6) million . - Adjusted EBITDA (see table included) was
$(947,568) compared to$(945,949) in the prior year.
Operational and Strategic Highlights
- Organic Clinic Growth: The Company achieved strong
23% organic growth during the quarter driven by added increased patient flow at its Wisconsin and Georgia clinics. Initiatives to improve patient awareness, expand geographic reach through telehealth capabilities and increase the comprehensive suite of fertility services all contributed to the growth. - Acquisition Strategy: The Company’s ongoing acquisition efforts have developed a pipeline of fertility clinics that it believes are interested in becoming part of INVO. The Company believes it offers target clinics a compelling opportunity to help build and become part of a public-company platform within the fertility industry.
- INVOcell Device Expansion: The Company has expanded clinical and embryology training support and improved pricing for its innovative INVOcell® technology, resulting in
130% year-over-year growth in INVOcell device revenue. This underscores the Company’s dual mission as an innovator of cutting-edge fertility solutions and a provider of compassionate, patient-centered clinical care. - Policy Updates: In October 2025, the U.S. Departments of Labor, Health and Human Services, and the Treasury announced that employers can now offer standalone benefit packages to employees interested in coverage for treatment of infertility, including IVF, representing a large opportunity to expand access to IVF coverage and make fertility more affordable and accessible for patients.
- Operational Efficiencies: The Company continues to focus its efforts to improve operating efficiencies at its clinics to drive enhanced profitability. The clinic efficiencies include a recent strategic partnership with Heidi Health to integrate its innovative AI-powered scribe platform.
Management Commentary
“This quarter showcased meaningful progress across the two core pillars of our growth strategy: strengthening organic performance within our existing operations and advancing accretive acquisition opportunities,” commented Steve Shum, CEO of INVO Fertility. “We saw a robust
“We are also executing effectively on our strategic initiatives to scale the business. Our pipeline of target clinics continues to grow, and we expect to complete at least one acquisition in the coming months, as more providers recognize the value of joining our mission to build an exciting, patient-centric platform. And lastly, our INVOcell device expansion initiatives delivered respectable performance, with expanded training support and improved pricing driving
“Across the organization, we also remain committed to operational efficiency to drive the business toward profitability as we grow,” Shum concluded.
Use of Non-GAAP Measure
Included in this press release is a reconciliation of Adjusted EBITDA. Additional financial tables are included in the Company’s Form 10-Q, which can be found on the Company’s website at invofertility.com/sec-filings or at sec.gov.
Adjusted EBITDA is a non-GAAP measure. This measure is not intended to be a substitute for those financial measures reported in accordance with GAAP. Adjusted EBITDA has been included because management believes that, when considered together with the GAAP figures, it provides meaningful information related to our operating performance and liquidity and can enhance an overall understanding of financial results and trends. Adjusted EBITDA may be calculated by us differently than other companies that disclose measures with the same or similar terms. See our attached financials for a reconciliation of this non-GAAP measure to the nearest GAAP measure.
About INVO Fertility
We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by our INVOcell® medical device (“INVOcell”) and US-based, profitable in vitro fertilization (“IVF”) clinics. We have two operational INVO Centers in the United States and one IVF clinic. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a more connected, intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination. For more information, please visit invofertility.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
INVO Fertility, Inc.
Steve Shum, CEO
978-878-9505
sshum@invofertility.com
Investor Contact
Lytham Partners, LLC
Robert Blum
602-889-9700
INVO@lythampartners.com
| INVO FERTILITY, INC. | |||||||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Revenue: | |||||||||||||||
| Clinic revenue | $ | 1,722,223 | $ | 1,418,011 | $ | 5,175,870 | $ | 4,763,131 | |||||||
| Product revenue | 34,871 | 15,140 | 82,063 | 82,903 | |||||||||||
| Total revenue | 1,757,094 | 1,433,151 | 5,257,933 | 4,846,034 | |||||||||||
| Operating expenses: | |||||||||||||||
| Cost of revenue | 1,127,749 | 988,465 | 3,266,281 | 2,700,347 | |||||||||||
| Selling, general and administrative expenses | 2,128,088 | 1,514,593 | 5,878,459 | 5,602,703 | |||||||||||
| Research and development expenses | - | - | - | 4,880 | |||||||||||
| Impairment loss | 1,397,353 | ||||||||||||||
| (Gain) loss on disposal of fixed assets | - | - | - | 511,663 | |||||||||||
| Depreciation and amortization | 136,741 | 230,495 | 540,940 | 687,793 | |||||||||||
| Total operating expenses | 3,392,578 | 2,733,553 | 11,083,033 | 9,507,386 | |||||||||||
| Loss from operations | (1,635,484 | ) | (1,300,402 | ) | (5,825,100 | ) | (4,661,352 | ) | |||||||
| Other income (expense): | |||||||||||||||
| Gain (loss) from equity method investment | 12,827 | (27,372 | ) | 8,012 | (9,422 | ) | |||||||||
| Gain on lease termination | - | - | - | 94,551 | |||||||||||
| Loss from debt extinguishment | (876,165 | ) | - | (1,568,435 | ) | (40,491 | ) | ||||||||
| Gain on settlement | - | - | 714,500 | - | |||||||||||
| Interest expense | (145,803 | ) | (273,629 | ) | (674,967 | ) | (824,536 | ) | |||||||
| Total other income (expense) | (1,009,141 | ) | (301,001 | ) | (1,520,890 | ) | (779,898 | ) | |||||||
| Net loss from continuing operations before income taxes | (2,644,625 | ) | (1,601,403 | ) | (7,345,990 | ) | (5,441,250 | ) | |||||||
| Income taxes | - | 29,259 | - | 31,095 | |||||||||||
| Net loss from continuing operations | (2,644,625 | ) | $ | (1,630,662 | ) | $ | (7,345,990 | ) | $ | (5,472,345 | ) | ||||
| Loss on disposition of NTI | - | - | (1,534,517 | ) | |||||||||||
| Loss from discontinued operations of NTI | - | - | (16,452,562 | ) | |||||||||||
| Net loss | (2,644,625 | ) | (1,630,662 | ) | (25,333,069 | ) | (5,472,345 | ) | |||||||
| Net loss from continuing operations per common share: | |||||||||||||||
| Basic | $ | (0.77 | ) | $ | (15.11 | ) | $ | (5.17 | ) | $ | (58.88 | ) | |||
| Diluted | $ | (0.77 | ) | $ | (15.11 | ) | $ | (5.17 | ) | $ | (58.88 | ) | |||
| Net loss from discontinued operations per common share: | |||||||||||||||
| Basic | $ | - | $ | - | $ | (12.66 | ) | $ | - | ||||||
| Diluted | $ | - | $ | - | $ | (12.66 | ) | $ | - | ||||||
| Net loss per common share: | |||||||||||||||
| Basic | $ | (0.77 | ) | $ | (15.11 | ) | $ | (17.83 | ) | $ | (58.88 | ) | |||
| Diluted | $ | (0.77 | ) | $ | (15.11 | ) | $ | (17.83 | ) | $ | (58.88 | ) | |||
| Weighted average number of common shares outstanding: | |||||||||||||||
| Basic | 3,447,622 | 107,949 | 1,420,853 | 92,944 | |||||||||||
| Diluted | 3,447,622 | 107,949 | 1,420,853 | 92,944 | |||||||||||
| Adjusted EBITDA | ||||||||||
| Three Months Ended | ||||||||||
| September 30 | ||||||||||
| 2025 | 2024 | |||||||||
| Net loss from continuing operations | $ | (2,644,625 | ) | $ | (1,630,662 | ) | ||||
| Interest expense | 144,067 | 86,980 | ||||||||
| Amortization of debt discount | 1,736 | 186,649 | ||||||||
| Tax expense (benefit) | - | 29,259 | ||||||||
| Stock-based compensation | 481,430 | 37,295 | ||||||||
| Stock option expense | 11,918 | 69,035 | ||||||||
| Non cash compensation for services | 45,000 | 45,000 | ||||||||
| Loss from debt extinguishment | 876,165 | - | ||||||||
| Depreciation and amortization | 136,741 | 230,495 | ||||||||
| Adjusted EBITDA | $ | (947,568 | ) | $ | (945,949 | ) | ||||
FAQ
What were INVO Fertility (IVF) Q3 2025 revenues and YoY change?
How did INVO Fertility's clinics perform in Q3 2025 (IVF)?
Did INVO Fertility (IVF) report a profit in Q3 2025?
What was INVO Fertility's Adjusted EBITDA for Q3 2025 (IVF)?
How fast is INVO Fertility's INVOcell device revenue growing (IVF)?
What operational initiatives did INVO Fertility highlight for Q3 2025 (IVF)?
